

## Nigeria Support for Injection Safety Devices

**This Decision Letter sets out the Programme Terms of a Programme.**

<b>1. Country:</b> Nigeria					
<b>2. Grant number:</b> 17-NGA-32a-X, 18-NGA-32a-X, 19-NGA-32a-X, 20-NGA-32a-X, 21-NGA-32a-X					
<b>3. Date of Decision Letter:</b> 21 March 2019					
<b>4. Date of the Partnership Framework Agreement:</b> 9 January 2014					
<b>5. Programme title:</b> Injection safety devices <sup>1</sup>					
<b>6. Programme duration<sup>2</sup>:</b> 2017-2021					
<b>7. Programme Budget (indicative)<sup>3</sup>:</b> (subject to the terms of the partnership framework agreement, if applicable)					
	2017-2018	2019	2020	2021	Total <sup>3</sup>
Programme Budget (US\$)	4,584,995	6,057,000	2,476,000	1,735,500	14,853,495
<b>8. Indicative Annual Amounts:</b> (subject to the terms of the Partnership Framework Agreement, if applicable) <sup>4</sup>					
<b>TOTAL injection safety devices to be purchased with Gavi funds in each year</b>	<b>2017-2018</b>	<b>2019</b>	<b>2020</b>		
Number of AD syringes		99,774,600	34,213,500		
Number of re-constitution syringes		10,537,700	3,893,400		
Number of safety boxes		1,213,550	419,200		
<b>Annual Amounts for injection safety devices for all Gavi vaccines (US\$)</b>	<b>\$4,584,995</b>	<b>\$6,057,000</b>	<b>\$1,751,500</b>		
<b>Injection safety devices to be purchased with Gavi funds in each year, <u>by type of support</u></b>					
<b>New Vaccine Support (NVS), Inactivated Polio Vaccine, 10 dose(s) per vial, LIQUID, Routine</b>	<b>2019</b>	<b>2020</b>			
Number of AD syringes	5,680,200	-			
Number of re-constitution syringes	-	-			
Number of safety boxes	62,500	-			

<sup>1</sup> This does not include vaccines.

<sup>2</sup> This is the entire duration of the Programme.

<sup>3</sup> This is the total amount endorsed by Gavi for the entire duration of the Programme.

<sup>4</sup> This is the amount that Gavi has approved.

Annual Amounts for injection safety devices for Vaccine (US\$)	\$257,500	-
<b>New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED, Follow-up campaign</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	24,471,400	-
Number of re-constitution syringes	2,716,400	-
Number of safety boxes	299,075	-
Annual Amounts for injection safety devices for Vaccine (US\$)	\$1,249,000	-
<b>New Vaccine Support (NVS), Measles, 10 dose(s) per vial, LYOPHILISED, 2D Routine</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	6,324,600	4,519,200
Number of re-constitution syringes	832,800	597,300
Number of safety boxes	78,750	56,300
Annual Amounts for injection safety devices for Vaccine (US\$)	\$330,000	\$236,000
<b>New Vaccine Support (NVS), Meningococcal type A, 10 dose(s) per vial, LYOPHILISED, Routine</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	8,158,200	-
Number of re-constitution syringes	1,201,500	-
Number of safety boxes	102,975	-
Annual Amounts for injection safety devices for Vaccine (US\$)	\$432,000	-
<b>New Vaccine Support (NVS), Meningococcal type A, 10 dose(s) per vial, LYOPHILISED, Mini catch-up campaign</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	29,208,800	-
Number of re-constitution syringes	3,242,200	-
Number of safety boxes	356,975	-
Annual Amounts for injection safety devices for Vaccine (US\$)	\$1,491,000	-
<b>New Vaccine Support (NVS), Pneumococcal (PCV10), 4 dose(s) per vial, LIQUID, Routine</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	3,005,400	-
Number of re-constitution syringes	-	-
Number of safety boxes	33,075	-
Annual Amounts for injection safety devices for Vaccine (US\$)	\$136,500	-

<b>New Vaccine Support (NVS), Yellow Fever, 10 dose(s) per vial, LYOPHILISED, Campaign</b>	<b>2019</b>	<b>2020</b>
Number of AD syringes	22,926,000	29,694,300
Number of re-constitution syringes	2,544,800	3,296,100
Number of safety boxes	280,200	362,900
Annual Amounts for injection safety devices for Vaccine (US\$)	\$2,161,000	\$1,515,500
<b>9. Procurement agency:</b> UNICEF. The Country shall release its co-financing payments each year to UNICEF.		
<b>10. Self-procurement:</b> Not applicable		
<b>11. Co-financing obligations:</b> Co-financing requirements are listed in the relevant vaccine Decision Letter.		

Signed by,



**On behalf of Gavi**

Hind Khatib-Othman

Managing Director, Country Programmes

21 March 2019